longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

LONGBIO-B

01779

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -29.74, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 65/78, the industry Median -5.53.

-29.74xP/E
HK$97.00Stock price
HK$-3.26Earnings per share
-29.74xP/E
Stock priceHK$97.00Earnings per shareHK$-3.26

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-40.35x
Typical range
-53.43x–-35.20x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0160320480640

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
09926HKAKESO
-74.70x83.25%HK$83.18B
09688HKZAI LAB
-14.60x505.86%HK$21.55B
07666HKMETIS TECHBIO-P
-44.80x96.70%HK$18.24B
01877HKJUNSHI BIO
-36.82x84.85%HK$17.04B
09606HKDUALITYBIO-B
-9.25x83.50%HK$15.32B
09887HKLEADS BIOLABS-B
-38.96x9.00%HK$11.97B
06855HKASCENTAGE
-6.93x18.21%HK$11.72B
02627HKAB&B BIO-TECH-B
-46.87x--HK$11.54B
01672HKASCLETIS-B
-14.60x78.59%HK$9.94B
02595HKGENFLEET-B
-6.45x78.96%HK$9.78B
01952HKEVEREST MED
-152.97x324.61%HK$9.50B
02616HKCSTONE PHARMA-B
-19.14x1.96%HK$9.23B
06938HKRIBOLIFE-B
-47.07x29.88%HK$9.19B
02493HKMABWELL-B
-8.38x--HK$9.07B
09966HKALPHAMAB-B
-38.05x--HK$7.71B
02171HKCARSGEN-B
-72.63x51.12%HK$7.46B
01779HKLONGBIO-B
-29.74x--HK$7.40B
02335HKMICOT PHARMA-B
-17.38x37.50%HK$7.29B
06872HKTENNOR THERAP-B
-40.78x--HK$6.54B
02256HKABBISKO-B
-11.37x300.95%HK$6.11B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.